# Accelerating innovation and ensuring the thoughtful withdrawal of lifeline medicines for people living with diabetes in Asia

**Authors:** Yutaka Seino, Daisuke Yabe, Sung Hee Choi, Chih‐Cheng Hsu, Chien‐Ning Huang, Altaisaikhan Khasag, Kathryn Tan, Kohjiro Ueki, Yuichiro Yamada, Zhanay A Akanov, Takashi Kadowaki

PMC · DOI: 10.1111/jdi.70063 · Journal of Diabetes Investigation · 2025-05-20

## TL;DR

The paper discusses the urgent need to protect insulin access in Asia while promoting innovation in diabetes care.

## Contribution

It highlights the ethical and policy considerations for balancing new treatments with equitable access to existing medicines.

## Key findings

- Coordinated regional action is needed to ensure insulin remains accessible in Asia.
- Policy frameworks must balance innovation with equitable diabetes care.
- Ethical imperatives are crucial in managing the withdrawal of essential medicines.

## Abstract

Coordinated regional action is urgently needed to safeguard insulin access in Asia amid global product realignment. This editorial emphasizes the ethical imperative and policy frameworks required to balance innovation with equitable, uninterrupted diabetes care.

## Linked entities

- **Diseases:** diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** diabetes (MESH:D003920)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12209500/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12209500/full.md

---
Source: https://tomesphere.com/paper/PMC12209500